Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — which accounted for 48% of overall sales in the first quarter of 2025. However, Lilly also boasts a wide range of products...